• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Identical gene regulation patterns of T3 and selective thyroid hormone receptor modulator GC-1.T3 和选择性甲状腺激素受体调节剂 GC-1 的基因调控模式相同。
Endocrinology. 2012 Jan;153(1):501-11. doi: 10.1210/en.2011-1325. Epub 2011 Nov 8.
2
Gene specific actions of thyroid hormone receptor subtypes.甲状腺激素受体亚型的基因特异性作用。
PLoS One. 2013;8(1):e52407. doi: 10.1371/journal.pone.0052407. Epub 2013 Jan 3.
3
Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice.GC-1对甲状腺受体的选择性调节可降低正常甲状腺功能小鼠的血脂,并刺激胆固醇逆向转运过程。
Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10297-302. doi: 10.1073/pnas.0504379102. Epub 2005 Jul 8.
4
Thyroid hormone receptor isoform-specific modification by small ubiquitin-like modifier (SUMO) modulates thyroid hormone-dependent gene regulation.甲状腺激素受体同工型特异性修饰的小泛素样修饰物 (SUMO) 调节甲状腺激素依赖性基因调控。
J Biol Chem. 2012 Oct 19;287(43):36499-508. doi: 10.1074/jbc.M112.344317. Epub 2012 Aug 28.
5
Thyroid Hormone Receptor α Plays an Essential Role in Male Skeletal Muscle Myoblast Proliferation, Differentiation, and Response to Injury.甲状腺激素受体α在雄性骨骼肌成肌细胞增殖、分化及损伤反应中起关键作用。
Endocrinology. 2016 Jan;157(1):4-15. doi: 10.1210/en.2015-1443. Epub 2015 Oct 9.
6
The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity.甲状腺激素受体β选择性激动剂GC-1对血脂和心脏活动有不同影响。
Endocrinology. 2000 Sep;141(9):3057-64. doi: 10.1210/endo.141.9.7681.
7
Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1.甲状腺受体配体。1. 对甲状腺受体β1具有选择性的激动剂配体。
J Med Chem. 2003 Apr 24;46(9):1580-8. doi: 10.1021/jm021080f.
8
Thyroid Hormone Receptor β Agonist Induces β-Catenin-Dependent Hepatocyte Proliferation in Mice: Implications in Hepatic Regeneration.甲状腺激素受体β激动剂诱导小鼠β-连环蛋白依赖性肝细胞增殖:对肝再生的影响
Gene Expr. 2016;17(1):19-34. doi: 10.3727/105221616X691631. Epub 2016 May 24.
9
Requirement for thyroid hormone receptor beta in T3 regulation of cholesterol metabolism in mice.小鼠胆固醇代谢的T3调节中甲状腺激素受体β的需求
Mol Endocrinol. 2002 Aug;16(8):1767-77. doi: 10.1210/me.2002-0009.
10
Thyroid Hormone Analogues: An Update.甲状腺激素类似物:更新。
Thyroid. 2020 Aug;30(8):1099-1105. doi: 10.1089/thy.2020.0071. Epub 2020 Apr 7.

引用本文的文献

1
Disturbed function of TBL1X has a differential effect on T3-regulated gene expression in two human liver cell models.TBL1X 功能障碍对两种人源肝细胞模型中 T3 调节基因表达的影响存在差异。
Eur Thyroid J. 2024 Oct 14;13(5). doi: 10.1530/ETJ-24-0162. Print 2024 Oct 1.
2
Synthesis and preclinical testing of a selective beta-subtype agonist of thyroid hormone receptor ZTA-261.甲状腺激素受体ZTA - 261的选择性β亚型激动剂的合成与临床前测试
Commun Med (Lond). 2024 Aug 6;4(1):152. doi: 10.1038/s43856-024-00574-z.
3
TRβ Agonism Induces Tumor Suppression and Enhances Drug Efficacy in Anaplastic Thyroid Cancer in Female Mice.TRβ 激动剂诱导女性小鼠甲状腺未分化癌的肿瘤抑制作用并增强药物疗效。
Endocrinology. 2023 Aug 28;164(10). doi: 10.1210/endocr/bqad135.
4
An extended transcription factor regulatory network controls hepatocyte identity.一个扩展的转录因子调控网络控制着肝细胞的身份。
EMBO Rep. 2023 Sep 6;24(9):e57020. doi: 10.15252/embr.202357020. Epub 2023 Jul 10.
5
Novel therapeutic targets for cholestatic and fatty liver disease.胆汁淤积性和脂肪性肝病的新型治疗靶点。
Gut. 2022 Jan;71(1):194-209. doi: 10.1136/gutjnl-2021-324305. Epub 2021 Oct 6.
6
Thyroid Hormone Receptor Beta as Tumor Suppressor: Untapped Potential in Treatment and Diagnostics in Solid Tumors.甲状腺激素受体β作为肿瘤抑制因子:实体瘤治疗与诊断中的未开发潜力
Cancers (Basel). 2021 Aug 24;13(17):4254. doi: 10.3390/cancers13174254.
7
Using Single-Cell RNA-Seq Data to Trace Tissue Cells Responsive to Thyroid Hormones.使用单细胞 RNA 测序数据追踪对甲状腺激素有反应的组织细胞。
Front Endocrinol (Lausanne). 2021 Feb 24;12:609308. doi: 10.3389/fendo.2021.609308. eCollection 2021.
8
Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH).甲状腺激素受体 β 激动剂在治疗非酒精性脂肪性肝炎(NASH)的临床开发中对基因转录的调控。
PLoS One. 2020 Dec 11;15(12):e0240338. doi: 10.1371/journal.pone.0240338. eCollection 2020.
9
Thyroid hormone receptor β1 stimulates to increase biliary phosphatidylcholine excretion in mice.甲状腺激素受体 β1 刺激以增加小鼠胆汁中磷脂酰胆碱的排泄。
J Lipid Res. 2018 Sep;59(9):1610-1619. doi: 10.1194/jlr.M084145. Epub 2018 Jun 12.
10
Potential Role of Thyroid Receptor β Agonists in the Treatment of Hyperlipidemia.甲状腺受体 β 激动剂在高脂血症治疗中的潜在作用。
Drugs. 2017 Oct;77(15):1613-1621. doi: 10.1007/s40265-017-0791-4.

本文引用的文献

1
In vivo activity of the thyroid hormone receptor beta- and α-selective agonists GC-24 and CO23 on rat liver, heart, and brain.甲状腺激素受体β和α选择性激动剂 GC-24 和 CO23 在大鼠肝脏、心脏和大脑中的体内活性。
Endocrinology. 2011 Mar;152(3):1136-42. doi: 10.1210/en.2010-0813. Epub 2011 Jan 14.
2
Impaired metabolic effects of a thyroid hormone receptor beta-selective agonist in a mouse model of diet-induced obesity.饮食诱导肥胖小鼠模型中甲状腺激素受体 β 选择性激动剂代谢作用受损。
Thyroid. 2010 May;20(5):545-53. doi: 10.1089/thy.2009.0318.
3
Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia.使用甲状腺激素类似物 eprotirome 治疗他汀类药物治疗的血脂异常。
N Engl J Med. 2010 Mar 11;362(10):906-16. doi: 10.1056/NEJMoa0905633.
4
Gaining ligand selectivity in thyroid hormone receptors via entropy.通过熵变获得甲状腺激素受体的配体选择性。
Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20717-22. doi: 10.1073/pnas.0911024106. Epub 2009 Nov 19.
5
A TRbeta-selective agonist confers resistance to diet-induced obesity.一种TRβ选择性激动剂可赋予对饮食诱导肥胖的抗性。
J Endocrinol. 2009 Nov;203(2):291-9. doi: 10.1677/JOE-08-0539. Epub 2009 Aug 27.
6
Isoform-specific transcriptional activity of overlapping target genes that respond to thyroid hormone receptors alpha1 and beta1.对甲状腺激素受体α1和β1产生应答的重叠靶基因的亚型特异性转录活性。
Mol Endocrinol. 2009 Nov;23(11):1758-75. doi: 10.1210/me.2009-0025. Epub 2009 Jul 23.
7
Differential presentation of protein interaction surfaces on the androgen receptor defines the pharmacological actions of bound ligands.雄激素受体上蛋白质相互作用表面的差异呈现决定了结合配体的药理作用。
Chem Biol. 2009 Apr 24;16(4):452-60. doi: 10.1016/j.chembiol.2009.01.016.
8
Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes.甲状腺激素模拟物:在动脉粥样硬化、肥胖症和2型糖尿病中的潜在应用。
Nat Rev Drug Discov. 2009 Apr;8(4):308-20. doi: 10.1038/nrd2830.
9
Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist.用肝脏靶向甲状腺激素受体激动剂治疗后大鼠和小鼠肝脏脂肪变性的减轻
Hepatology. 2009 Feb;49(2):407-17. doi: 10.1002/hep.22572.
10
Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141.甲状腺受体β亚型选择性激动剂KB-141的抗肥胖、抗糖尿病及降脂作用
J Steroid Biochem Mol Biol. 2008 Sep;111(3-5):262-7. doi: 10.1016/j.jsbmb.2008.06.010. Epub 2008 Jun 22.

T3 和选择性甲状腺激素受体调节剂 GC-1 的基因调控模式相同。

Identical gene regulation patterns of T3 and selective thyroid hormone receptor modulator GC-1.

机构信息

Methodist Hospital Research Institute, F8-045, 6565 Fannin Street, Houston, Texas 77030, USA.

出版信息

Endocrinology. 2012 Jan;153(1):501-11. doi: 10.1210/en.2011-1325. Epub 2011 Nov 8.

DOI:10.1210/en.2011-1325
PMID:22067320
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3249679/
Abstract

Synthetic selective thyroid hormone (TH) receptor (TR) modulators (STRM) exhibit beneficial effects on dyslipidemias in animals and humans and reduce obesity, fatty liver, and insulin resistance in preclinical animal models. STRM differ from native TH in preferential binding to the TRβ subtype vs. TRα, increased uptake into liver, and reduced uptake into other tissues. However, selective modulators of other nuclear receptors exhibit important gene-selective actions, which are attributed to differential effects on receptor conformation and dynamics and can have profound influences in animals and humans. Although there are suggestions that STRM may exhibit such gene-specific actions, the extent to which they are actually observed in vivo has not been explored. Here, we show that saturating concentrations of the main active form of TH, T(3), and the prototype STRM GC-1 induce identical gene sets in livers of euthyroid and hypothyroid mice and a human cultured hepatoma cell line that only expresses TRβ, HepG2. We find one case in which GC-1 exhibits a modest gene-specific reduction in potency vs. T(3), at angiopoietin-like factor 4 in HepG2. Investigation of the latter effect confirms that GC-1 acts through TRβ to directly induce this gene but this gene-selective activity is not related to unusual T(3)-response element sequence, unlike previously documented promoter-selective STRM actions. Our data suggest that T(3) and GC-1 exhibit almost identical gene regulation properties and that gene-selective actions of GC-1 and similar STRM will be subtle and rare.

摘要

合成选择性甲状腺激素(TH)受体(TR)调节剂(STRM)在动物和人类中显示出对血脂异常的有益作用,并减少肥胖、脂肪肝和胰岛素抵抗在临床前动物模型中。STRM 与天然 TH 不同,它们优先与 TRβ亚型结合,而不是 TRα,更多地进入肝脏,而较少进入其他组织。然而,其他核受体的选择性调节剂表现出重要的基因选择性作用,这归因于对受体构象和动力学的不同影响,并可能对动物和人类产生深远影响。尽管有迹象表明 STRM 可能表现出这种基因特异性作用,但它们在体内实际观察到的程度尚未得到探索。在这里,我们表明,饱和浓度的主要活性形式的 TH,T(3),和原型 STRM GC-1 在甲状腺功能正常和甲状腺功能减退的小鼠肝脏和仅表达 TRβ 的人培养肝癌细胞系 HepG2 中诱导相同的基因集。我们发现一种情况,即 GC-1 在 HepG2 中对血管生成素样因子 4 的效力相对于 T(3) 表现出适度的基因特异性降低。对后者的影响的研究证实,GC-1 通过 TRβ 直接诱导该基因,但这种基因选择性活性与不寻常的 T(3)-反应元件序列无关,与以前记录的启动子选择性 STRM 作用不同。我们的数据表明,T(3)和 GC-1 表现出几乎相同的基因调控特性,而 GC-1 和类似的 STRM 的基因选择性作用将是微妙和罕见的。